A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD
TM Siler, AC Donald, D O'Dell, A Church… - International Journal of …, 2016 - Taylor & Francis
Background The combination of the inhaled muscarinic antagonist umeclidinium (UMEC)
with the long-acting β2-agonist vilanterol (VI) has been shown to provide significant …
with the long-acting β2-agonist vilanterol (VI) has been shown to provide significant …
[HTML][HTML] Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD
JF Donohue, MR Maleki-Yazdi, S Kilbride, R Mehta… - Respiratory …, 2013 - Elsevier
Study objective To examine the efficacy and safety of the once-daily, inhaled, long-acting
muscarinic antagonist/β 2-agonist combination umeclidinium/vilanterol (UMEC/VI) …
muscarinic antagonist/β 2-agonist combination umeclidinium/vilanterol (UMEC/VI) …
28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial
G Feldman, RR Walker, J Brooks, R Mehta… - Pulmonary …, 2012 - Elsevier
BACKGROUND: Umeclidinium (UMEC; GSK573719) is a new long-acting muscarinic
antagonist (LAMA) currently in development in combination with vilanterol (VI), an inhaled …
antagonist (LAMA) currently in development in combination with vilanterol (VI), an inhaled …
Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study
J Zheng, N Zhong, A Newlands, A Church… - International Journal of …, 2015 - Taylor & Francis
Background Combination of the inhaled long-acting muscarinic antagonist umeclidinium
(UMEC; GSK573719) with the long-acting β2-agonist vilanterol (VI) is an approved …
(UMEC; GSK573719) with the long-acting β2-agonist vilanterol (VI) is an approved …
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results …
JF Donohue, D Niewoehner, J Brooks, D O'Dell… - Respiratory …, 2014 - Springer
Background The long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC) and the
combination of UMEC with the long-acting β 2-agonist (LABA) vilanterol (UMEC/VI) are …
combination of UMEC with the long-acting β 2-agonist (LABA) vilanterol (UMEC/VI) are …
Once-daily umeclidinium/vilanterol 125/25 μg therapy in COPD: a randomized, controlled study
Background Combination long-acting bronchodilator therapy may be more effective than
long-acting bronchodilator monotherapy in COPD. Our objectives were to compare the …
long-acting bronchodilator monotherapy in COPD. Our objectives were to compare the …
Long-term safety and tolerability of umeclidinium/vilanterol and umeclidinium in COPD
J Donohue, D Niewoehner, J Brooks, D O'Dell… - 2013 - Eur Respiratory Soc
Background: The long-acting muscarinic antagonist umeclidinium (UMEC) is in
development as monotherapy and in combination with the long-acting beta-2 agonist …
development as monotherapy and in combination with the long-acting beta-2 agonist …
Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy
KS Babu, JB Morjaria - Therapeutic Advances in Chronic …, 2017 - journals.sagepub.com
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality
and health care expenditure throughout the world. COPD guidelines recommend the use of …
and health care expenditure throughout the world. COPD guidelines recommend the use of …
Umeclidinium plus vilanterol versus placebo, umeclidinium, or vilanterol monotherapies for chronic obstructive pulmonary disease: a meta-analysis of randomized …
L Wang, C Zhai, Y Liu, Y Liu, S Jiang - Clinical drug investigation, 2016 - Springer
Background The role of umeclidinium plus vilanterol as a combination therapy for chronic
obstructive pulmonary disease (COPD) has not yet been clearly defined. Objective The aim …
obstructive pulmonary disease (COPD) has not yet been clearly defined. Objective The aim …
Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study
R Mehta, D Kelleher, A Preece, S Hughes… - International journal of …, 2013 - Taylor & Francis
Background The combination of umeclidinium (UMEC), a long-acting muscarinic receptor
antagonist, and vilanterol (VI), a selective long-acting β2 agonist, is in development for the …
antagonist, and vilanterol (VI), a selective long-acting β2 agonist, is in development for the …
相关搜索
- quality of life umeclidinium vilanterol
- quality of life patients with copd
- umeclidinium vilanterol patients with copd
- umeclidinium vilanterol maintenance therapy
- systemic exposure umeclidinium and vilanterol
- effect of verapamil umeclidinium and vilanterol
- open label umeclidinium and vilanterol
- combination with vilanterol tolerability of umeclidinium
- asian patients efficacy and safety
- place in therapy latest evidence
- umeclidinium vilanterol life in patients